Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status.

Abstract

Glioblastoma is a malignant brain tumor and one of the most lethal cancers in human. Temozolomide constitutes the standard chemotherapeutic agent, but only shows limited efficacy in glioblastoma patients with unmethylated O-6-methylguanine-DNA methyltransferase (MGMT) promoter status. Recently, it has been shown that glioblastoma cells communicate via particular ion-channels-so-called gap junctions. Interestingly, inhibition of these ion channels has been reported to render MGMT promoter-methylated glioblastoma cells more susceptible for a therapy with temozolomide. However, given the percentage of about 65% of glioblastoma patients with an unmethylated MGMT promoter methylation status, this treatment strategy is limited to only a minority of glioblastoma patients. In the present study we show that-in contrast to temozolomide-pharmacological inhibition of intercellular cytosolic traffic via gap junctions reinforces the antitumoral effects of chemotherapeutic agent lomustine, independent of MGMT promoter methylation status. In view of the growing interest of lomustine in glioblastoma first and second line therapy, these findings might provide a clinically-feasible way to profoundly augment chemotherapeutic effects for all glioblastoma patients.

• Authors: Matthias Schneider, Anna-Laura Potthoff, Bernd O Evert, Marius Dicks, Denise Ehrentraut, Andreas Dolf, Elena N C Schmidt, Niklas Schäfer, Valeri Borger, Torsten Pietsch, Mike-Andrew Westhoff, Erdem Güresir, Andreas Waha, Hartmut Vatter, Dieter H Heiland, Patrick Schuss, Ulrich Herrlinger
• Journal: Pharmaceuticals (Basel, Switzerland) (Pharmaceuticals (Basel)) Vol. 14 Issue 3 (Feb 27 2021) ISSN: 1424-8247 [Print] Switzerland
• PMID: 33673490 (Publication Type: Journal Article)